Dr. Reddy’s has secured a position in the prestigious S&P Dow Jones Sustainability World Index (DJSI World) for 2023. The company has also successfully maintained its position in the Dow Jones Sustainability Index for Emerging Markets (DJSI EM) for the eighth consecutive year.
The recognition in these indices is based on Dr. Reddy’s performance in the S&P Global Corporate Sustainability Assessment (S&P Global CSA) and additional screening criteria. In the 2023 S&P Global CSA, Dr. Reddy’s scored an impressive 77 out of 100, excelling in areas such as innovation management, impact on access to healthcare, climate risk management, and resource efficiency and circularity.
The company attained the sixth-highest score out of 347 companies assessed in the pharmaceuticals industry by S&P Global CSA. As reported by businesswire, Dr. Reddy’s S&P Global ESG score, measuring the company’s performance and management of material Environmental, Social, and Governance (ESG) risks, opportunities, and impact, stands at 78 out of 100.
